Navigation Links
Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
Date:5/15/2008

- Safety and Efficacy Clinical Data from Prostate, Colorectal and Ovarian

Cancers - - Company to Hold Investor Event on Sun., June 1 with Oncology Experts -

SOUTH SAN FRANCISCO, Calif., May 15 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that the Company will present data from three clinical trials of picoplatin, in various tumor types and combinations, at poster sessions during the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) at McCormick Place in Chicago. The Company will present preliminary data from its ongoing Phase 2 clinical trial of picoplatin in colorectal cancer (CRC) and updated data from its Phase 1 CRC trial, data from its ongoing Phase 2 trial of picoplatin in hormone refractory prostate cancer (HRPC), as well as data from a Phase 1 trial of picoplatin in advanced solid tumors, including ovarian cancer.

Picoplatin, the Company's lead product candidate, is a new generation platinum chemotherapy agent with the potential to become a platform product addressing multiple indications, administered either alone or in combination with other chemotherapy and targeted agents.

"We are continuing to execute on our clinical strategy, demonstrating that picoplatin is a platform product, with broad utility in multiple solid tumor types," said Ronald Martell, president and chief operating officer of Poniard Pharmaceuticals. "The data from these trials that we will present at ASCO should illustrate the significant clinical value of picoplatin to patients with a broad range of tumor types, including those with colorectal, prostate and ovarian cancer. These results should
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
2. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
3. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
4. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
5. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
6. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
7. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
8. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
9. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
10. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
11. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...a, Nov. 25 /PRNewswire-Asia-FirstCall/ -- China Sk...he Company") (Nasdaq: CSKI ), a,leading fully int...ucing,over-the-counter drugs in the People,s Repub...pany recently passed the Chinese National Institut... Products ("ICPBP") examination,for two of its new...
(Date:11/25/2009)... Nov. 25 According to Millennium R...al technology market intelligence, the nearly $3 b...continue to see rapid growth over the next five ye...S Markets for Trauma Devices 2010 report finds ...he next five years, with competitors introducing s...
(Date:11/25/2009)...herlands and JOHANNESBURG, November 25 /PRNewswire... Pyxis Discovery announced today,that they have si...oth,companies, services. , Pyxis,s world ...xpertise,will be coupled with iThemba,s service di...y support to projects identified through Pyxis,in...
Breaking Medicine Technology:China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2Home For the Holidays 3A MyShrink com Announces the Second in its Successful Six Part Webinar Series 3A 26quot 3BAbandonment 3A The Hidden Fear 26quo 62006 1Home For the Holidays 3A MyShrink com Announces the Second in its Successful Six Part Webinar Series 3A 26quot 3BAbandonment 3A The Hidden Fear 26quo 62006 2Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery 62004 1Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery 62004 2Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery 62004 3Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery 62004 4NCL Security Launches EyeCentral Video Platform for the Security Industry to Generate Recurring Monthly Revenue for Central Stations and Security Deal 62002 1NCL Security Launches EyeCentral Video Platform for the Security Industry to Generate Recurring Monthly Revenue for Central Stations and Security Deal 62002 2
..., April 17 Schering-Plough,Corporation (NYSE: SG...nt of,chronic hepatitis C virus (HCV) infection, a...dy as well as from several other clinical studies,...ETOL(R) (ribavirin, USP),combination therapy will ...tudy of the Liver (EASL) 43rd annual meeting in Mi...
... April 16 Kosan Biosciences,Incorporated (Nasdaq:...tary,nuclear export inhibitors (NEI) showing poten...ility in leukemia xenograft models, and further,el...orrelating inhibition,of the target CRM1 with indu...pared to normal cells. Data on Kosan,s NEIs were p...
Other Medicine Technology:Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 7Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 8Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 9Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 2Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 3Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 4
(Date:11/27/2009)... Biotech firm Replikins Ltd. tod...1N1 virus genomic data. It shows that the lethali...s.d. 4.5) during the virus,s current outbreak in t...his week of 2.0 (s.d. 0.1). The H1N1 infectivity c... Boston (PRWEB) November 27, 2009 -- Bio...
(Date:11/27/2009)... , NEUILLY-SUR-SEINE, France, Nov. 27 /PRNewsw... professional cycling team dedicated to ethical sp...ng champions, announced today that it will become ...itions Optical as a new sponsor of the team. Trans... of adaptive eyewear, offering the most advanced p...
(Date:11/27/2009)... rates to bring unprecedented medical, economic bu...7 (HealthDay News) -- The number of people with di...over the next 25 years, a new study predicts. ,...million people with the disease, up from 23.7 mill...ating people with diabetes will triple, the study ...
(Date:11/27/2009)... Specialist manufacturers who us...s are saving millions of dollars by bringing in te...ss. Increasing numbers of pro-active medical manuf...at the concept stage of their projects, ensuring t...esign processes or potentially outdated technology...
(Date:11/26/2009)...e next 25 years, the number of Americans living wi....7 million in 2009 to 44.1 million in 2034. Over t...riple, rising from $113 billion to $336 billion, e... researchers based at the University of Chicago re... The number of those with diabetes covered by Medi...
Breaking Medicine News(10 mins):Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3
..., SAN DIEGO, Jan. 6 NuVasive, Inc. (Nasdaq: NU...ng products for minimally disruptive surgical trea...kianov, Chairman and Chief Executive Officer, is s...2009, at 11:00 a.m. PT. , , A live Web cast of th...
..., SAN DIEGO, Jan. 6 Orexigen(R) Therapeutics,...ny focused on the treatment of,obesity, today anno...h Annual,J.P. Morgan Healthcare Conference. The de... California, Webcast link: , http://metameetin...
..., Frontier Service Design Creates Tangible Value b... Jan. 6 Frontier Service Design, LLC, a firm that...s that create new and recurring revenue streams fo... around business opportunities that yield new sour...
..., Completed Phase 2 Bladder Augment Trial and Plan...kthrough in Kidney Regeneration Program: Preclini...ON, Pa., Jan. 6 Tengion Inc., a clinical-stage or...ef executive officer, is scheduled to present at t...
..., MILAN, Italy, Jan. 6 A pancreatic cancer pa...reated using a new, faster form of,radiotherapy th... while,extending more advanced care to more patien.... , "We see three major benefits with RapidArc...
..., Rock & Roll Hall of Fame inductees Jackson B...ing attention to the nation,s biggest problem: the...nt Emissary, a DC-based event planning company, an...ll Blue Diamond Ball will be held January 20, 2009...
Other Medicine News:Health News:NuVasive to Present at 27th Annual J.P. Morgan Healthcare Conference 2Health News:First Service Design Firm Launches in United States 2Health News:Tengion to Present at 27th Annual JP Morgan Healthcare Conference 2Health News:First RapidArc Radiotherapy Treatment in Italy Takes Place at Leading Milan Cancer Center 2Health News:First RapidArc Radiotherapy Treatment in Italy Takes Place at Leading Milan Cancer Center 3Health News:Health for All Blue Diamond Ball Scheduled to Celebrate Obama's Inauguration 2
...le ergonomic chairs with concave seats and large b... like seats, backrests, armrests, and casters and ...mance in a variety of environments including: indu...ntrol, health care and office. • With cast al...
...le ergonomic chairs with concave seats and large b... like seats, backrests, armrests, and casters and ...mance in a variety of environments including: indu...ntrol, health care and office. • With cast al...
BEC/1Q-ERB - Cast Aluminum Base - Model 1Q72-ERB
BET/1P-ERB - Tubular Base - Model 1P63
Medicine Products: